Oncotelic Therapeutics (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, moving the company closer to commercializing an AI-powered good manufacturing practices (GMP) manufacturing services platform. The platform, deployed at SAPU Bio—the company’s 45%-owned sterile injectable cGMP manufacturing joint venture—integrates Oncotelic’s proprietary PDAOAI platform with autonomous robotic systems to support intelligent pharmaceutical manufacturing.
The Phase 2 deployment expands PDAOAI’s capabilities across sterile manufacturing operations, including electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. According to the company, the integrated platform creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO).
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. The initiative underscores the growing trend of artificial intelligence and robotics in pharmaceutical production, where automation can enhance efficiency, reduce human error and ensure compliance with stringent regulatory standards.
The implications of this advancement extend beyond Oncotelic’s own operations. By offering software licensing and automation deployment, the company could position itself as a technology provider for other pharmaceutical manufacturers seeking to modernize their facilities. The move also aligns with industry-wide shifts toward Industry 4.0, where smart manufacturing and data-driven processes are becoming critical for competitiveness.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio.
The completion of Phase 2 objectives marks a significant milestone for Oncotelic as it transitions from development to commercialization. With the BIO International Convention 2026 as a showcase opportunity, the company aims to attract partners and clients for its technology-enabled CDMO services. For more information, visit the company’s newsroom at https://nnw.fm/OTLC.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Advances AI-Powered GMP Manufacturing Platform with Completion of Phase 2 Objectives.